WO1995031464A1 - New agonist compounds - Google Patents
New agonist compounds Download PDFInfo
- Publication number
- WO1995031464A1 WO1995031464A1 PCT/SE1995/000504 SE9500504W WO9531464A1 WO 1995031464 A1 WO1995031464 A1 WO 1995031464A1 SE 9500504 W SE9500504 W SE 9500504W WO 9531464 A1 WO9531464 A1 WO 9531464A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- aryl
- formula
- compounds
- hydroxy
- Prior art date
Links
- 0 CN(CC[C@]12c(c(C3)ccc4OC)c4O[C@@]1(*)C(C=C1)=O)C3[C@@]21O* Chemical compound CN(CC[C@]12c(c(C3)ccc4OC)c4O[C@@]1(*)C(C=C1)=O)C3[C@@]21O* 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Definitions
- the present invention is related to novel ⁇ opioid receptor agonists as well as to their pharmaceutically acceptable salts, a process for their preparation and their use in the manufacture of pharmaceutical preparations.
- ⁇ , K and ⁇ Three major types of opioid receptors, ⁇ , K and ⁇ , are known and characterized. The identification of different opioid receptors has lead to efforts to develop specific ligands for these receptors. These ligands are known to be useful for at least two purposes: a) to enable the more complete characterization of these different receptors, and b) to facilitate the identification of new analgesic drugs.
- Analgesic drugs having specificity for an individual opioid receptor type have been demonstrated to have fewer side effects (e.g. respiratory depression, constipation, dependence), and in cases in which tolerance to one drug has developed, a second drug with different opioid receptor specificity may be effective.
- DADLE intrathecal application
- a partially ⁇ -selective analgesic peptide, for morphine in a human cancer patient with morphine tolerance has been demonstrated (E.S. Krames et al., Pain, Vol. 24:205-209,1986).
- Evidence that a ⁇ -selective agonist could be a potent analgesic with less tolerance and dependence liability was presented by Frederickson et al. (Science, Vol.
- Naloxone precipitation of withdrawal after chronic administration of metkephamid and morphine in rats showed that metkephamid-treated animals exhibited fewer withdrawal symptoms than those given morphine, scoring only a little above the saline control group. Metkephamid produced substantially less respiratory depression than morphine.
- DPDPE Another ⁇ -selective peptide, [D-Pen 2 , D-Pen 5 ]enkephalin (DPDPE) produces potent analgesic effects while showing little if any respiratory depression (C.N. May, Br.J. Pharmacol., Vol.98:903-913,1989). DPDPE was found not to produce gastrointestinal side effects (e.g. constipation) (T.F.Burks, Life Sci., Vol.43:2177- 2181,1988). Since it is desireable that analgesics are stable against peptidases and are capable of entering the CNS easily, non-peptide analgesics are much more valuable.
- BW373U86 - a piperazine derivative a non-peptide, ⁇ -selective opioid agonist, BW373U86 - a piperazine derivative.
- BW 373U86 is reported to be a potent analgesic which does not produce physical dependence (P.H.K. Lee et al., JPharmacol.Exp.Ther., Vol. 267:983-987,1993).
- the present invention provides novel analgesic compounds of the formula I
- R represents C j -C 8 alkyl or hydrogen
- 1* 2 represents hydrogen, hydroxy, 0,-C 8 alkoxy; C j -C 6 alkenyloxy; C 7 -C 16
- arylalkyloxy wherein the aryl is C 6 -C 10 aryl and the alkyloxy is C 1 -C 6 alkyloxy; C 7 -
- aryl is C 6 -C 10 aryl
- alkanoyloxy is C ] -C 6 alkanoyloxy
- R g represents hydrogen, C.-C 6 alkyl; C 1 -C 6 alkenyl; C 7 -C 16 arylalkyl wherein the
- aryl is C 6 -C 10 aryl and the alkyl is C 1 -C 6 alkyl; C 7 -C 16 arylalkenyl wherein the aryl
- alkenyl is C ⁇ -C 8 alkenyl; hydroxy(C 1 -C 6 )alkyl; alkoxyalkyl
- alkoxy is C C 6 alkoxy and the alkyl is C 1 -C 6 alkyl; C0 2 H; C0 2 (C C 6 alkyl);
- R 4 is hydrogen, hydroxy; C j -C 6 alkoxy; C 7 -C 16 arylalkyloxy wherein the aryl is C 6 -
- C 10 aryl and the alkyloxy is C 1 -C 6 akyloxy; C ] -C 6 alkenyloxy; C 1 -C 6 alkanoyloxy; C 7 -C 16 arylalkanoyloxy wherein the aryl is C 6 -C 10 aryl and the alkanoyloxy is C,-
- alkyloxyalkoxy wherein alkyloxy is C 1 -C 4 alkyloxy and alkoxy is
- R 5 and R 6 each independently represent hydrogen; OH; C j -C 8 alkoxy;
- alkenyl C 7 -C 16 arylalkyl wherein the aryl is C 6 -C 10 aryl and the alkyl is C.-C 6
- alkyl C 7 -C 16 arylalkenyl wherein the aryl is C 6 -C 10 aryl and the alkenyl is C ] -C 6
- aryl is unsubstituted or mono-, di- or trisubstituted independently with hydroxy, halo, nitro, cyano, thiocyanato, trifluoromethyl, C J -C J alkyl, C,-C 3
- CO ⁇ j -C 8 alkyl CO ⁇ j -C 8 alkyl); amino; (C j ⁇ monoalkyDamino, (C j -C j dialkyDamino, C 5 -C 6 cycloalkylamino, (C ⁇ C g alkanoyDamido, SH, S0 3 H, S0 3 (C,-C 3 alkyl), S0 2 (C.-C 3
- Aryl may be unsubstituted or mono-, di- or trisubstituted independently with hydroxy, halo, nitro, cyano, thiocyanato, trifluoromethyl, C ⁇ C g alkyl, C ⁇ C g
- Pharmaceutically and pharmacologically acceptable salts of the compounds of formula I include suitable inorganic salts and organic salts which can be used according to the invention.
- suitable inorganic salts which can be used are HCl salt, HBr salt, sulfuric acid salt and phosphoric acid salt.
- organic salts which can be used according to the invention are methanesulfonic acid salt, salicylic acid salt, fumaric acid salt, maleic acid salt, succinic acid salt, aspartic acid salt, citric acid salt, oxalic acid salt and orotic acid salt. These examples are however not in any way limiting the salts which could be used according to the invention.
- novel ⁇ -selective morphinane derivatives of the formula I are useful as analgesics without having dependence liability. They may be administered parenterally or non-parenterally. Specific routes of administration include oral, rectal, topical, nasal, ophthalmic, subcutaneous, intramuscular, intravenous, intrathecal, transdermal, intraartherial, bronchial, lymphatic and intrauterine administration. Formulations suitable for parenteral and oral administration are preferred.
- R j is selected from hydrogen, methyl, ethyl, n-propyl or isopropyl;
- R 2 is selected from methoxy, ethoxy, n-propyloxy, benzyloxy, benzyloxy
- R g is selected from hydrogen, methyl, ethyl, benzyl or allyl;
- R 4 is selected from hydroxy, methoxy, methoxymethoxy or acetyloxy
- R 5 and R 6 are each and independently selected from hydrogen, nitro, cyano,
- X is selected from O, NH, NCH 3 , N-benzyl, N-allyl.
- R is CH 3 ;
- R j is selected from methoxy, ethoxy, n-propyloxy, benzyloxy or benzyloxy substituted in the aromatic ring with chlorine 3 is selected from hydrogen or CH 3 ;
- R 4 is hydroxy
- R 5 and R 6 are each and independently selected from hydrogen, C0 2 H, CONH 2 ,
- S0 2 NH 2 or S0 2 CH 3 ; and X is selected from O or NH.
- aralkyl wherein the aryl is C 6 -C 10 aryl and the alkyl is C j -C 6 alkyl; alkoxyalkyl
- alkoxy is C ⁇ -C 6 alkoxy and the alkyl is C,-C 6 alkyl; C0 2 (C 1 -C 6 alkyl);
- C,-C 6 alkanoyl may be obtained by the following methods:
- dialkylsulfates fluorosulfonic acid alkyl esters, alkylsulfonic acid alkyl esters, arylsulfonic acid alkylesters, alkyl halides, alkenyl halides, aralkyl halides, alkylsulfonic acid aralkyl esters, arylsulfonic acid aralkyl esters, arylalkenyl halides or chloroformates, in solvents such as tetrahydrofurane or diethyl ether using a strong base such as n-butyl lithium, lithium diethyl amide or lithium diisopropyl amide at low temperatures (-20 to -80 °C) (s.
- R is C 1 -C 6 alkyl; C 1 -C 6 alkenyl; C 7 -C 16 arylalkyl, wherein the aryl is C 6 -
- alkenyl is C j -C 6 alkenyl; alkoxyalkyl wherein the alkoxy is C 1 -C 6
- alkoxy and the alkyl is C 1 -C 6 alkyl; C0 2 (C.-C 6 alkyl);
- R is as defined above or being hydrogen
- R by reaction with performic acid (H. Schmidhammer et al., Helv.Chim.Acta, Vol. 71:1801-1804, 1988) or m- chloroperbenzoic acid, at a temperature between 0 and 60 ° C.
- the preferred procedure is the reaction with performic acid at 0-10°C (H.Schmidhammer et.al., Helv. Chim. Acta. Vol. 71:1801-1804, 1988).
- R is C j -C 8 alkyl, C 1 -C 6 alkenyl, C 7 -C 16 arylalkyl wherein the aryl is C 6 -C 10 aryl
- alkyl is C 1 -C 6 alkyl, C 7 -C ]6 arylalkenyl wherein the aryl is C 6 -C 10 aryl and
- the alkenyl is C 1 -C 6 alkenyl, 0,-C 8 alkanoyl, C 7 -C 16 arylalkanoyl wherein the aryl
- alkanoyl is C 1 -C 6 alkanoyl, C 7 -C 16 arylalkenoyl wherein the
- aryl is C 6 -C 10 aryl and the alkenoyl is C : -C 6 alkenoyl;
- R 2 is hydrogen; C 1 -C 6 alkyl; C 1 -C 6 alkenyl C 7 -C 16 arylalkyl wherein the aryl is C 6 -
- alkenyl is C 1 -C 6 alkenyl; alkoxyalkyl wherein the alkoxy is C,-C 6
- alkoxy and the alkyl is C C 6 alkyl; C0 2 (C r C 6 alkyl);
- R is C j -C 6 alkyl, C 7 -C 16 arylalkyl wherein the aryl is C 6 -C 10 aryl and the alkyl is
- alkanoyl is C j -C 6 alkanoyl
- R j is hydrogen; C 1 -C 6 alkyl, C 7 -C ]6 arylalkyl wherein the aryl is C 6 -C 10 aryl and the
- alkyl is C ] -C 6 alkyl; alkoxyalkyl wherein the alkoxy is C j -C 6 alkoxy and the alkyl
- R 7 and R j are as defined above in formula (V).
- Alkylation using alkyl halides, alkyl sulfates, sulfonic acid esters, aralkyl halides, arylalkenyl halides, or acylation using carbonic acid chlorides, carbonic acid anhydrides, or carbonic acid esters affords compounds of formula (VII)
- R 3 is C,-C 6 alkyl, C 7 -C 16 arylalkyl wherein the aryl is C 6 -C 10 aryl and the alkyl is
- alkanoyl is C ⁇ -C 6 alkanoyl, alkyloxyalkyl wherein alkyloxy is C J - J alkyloxy
- alkyl is C j -C 6 alkyl
- R., and R 3 are as defined above in formula (V) and (VII),
- R v R j and R g are as defined above in formula (V) and (VII).
- N-alkylation can be accomplished with alkyl halide or dialkyl sulfate in solvents such as dichloro methane, chloroform or N,N-dimethyl formamide in the presence of a base such as sodium hydrogen carbonate or potassium carbonate to yield derivatives of formula (X)
- R., R 2 and R g are as defined above in formula (V) and (VII), and Y is methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, isobutyl, tert-butyl, 2-pentyl, 3-pentyl, 2-hexyl or 3-hexyl.
- Ether cleavage can be carried out as described for compounds of formula (V) giving derivatives of formula (XI)
- R and R j are as defined above in formula (V), and Y is as defined above in formula (X).
- R g are as defined above in formula (V) and (VII), is analogous to the reaction sequence and procedures described above. Further conversion into compounds of the formula (I) wherein R j is hydroxy is described below.
- R j is hydrogen
- R, and R j are as defined above and n is 0-5.
- C 6 alkyl) 2 ,S0 2 NH 2 ,S0 2 (C ] -C 6 alkyl) or the like may be employed.
- the reaction may be carried out at a temperature between 20 and 160 °C, preferably between 20 and 80 °C.
- CON(C C 6 alkyl) 2 ,S0 2 NH 2 ,S0 2 (C 1 -C 6 alkyl) or the like may be employed.
- the active ingredient may be formulated to an injection, capsule, tablet, suppository, solution or the like. Oral formulation and injection are preferably employed.
- the pharmaceutical formulation may comprise the ⁇ -selective agonist alone or may also comprise expedients such as stabilizers, buffering agents, diluents, isotonic agents, antiseptics and the like.
- the pharmaceutical formulation may contain the above described active ingredient in an amount of 1-95 % by weight, preferably 10-60 % by weight.
- the dose of the active ingredient may appropriately be selected depending on the objects of administration, administration route and conditions of the patients.
- the active ingredient is administered in doses between 1 mg and 800 mg per day in case of administration by injection and in doses between 10 mg and 5 g per day in case of oral administration.
- the preferred dose for injection is 20-200 mg per day and the preferred amount for oral administration 50-800 mg per day.
- ⁇ -Selective agonism was assessed using the electrical stimulated guinea-pig ileal longitudinal muscle preparations (GPI; containing m and k opioid receptors) (P.W. Schiller et al., Biochem. Biophys. Res. Commun., Vol. 58: 11-18, 1978; J. Di Maio et. al., J. Med. Chem., Vol. 25: 1432-1438, 1982) and mouse vas deferens preparation (MVD: containing ⁇ , K and ⁇ opioid receptors). The activities of the compounds to inhibit the contraction of the organs were measured. In the GPI, compounds 1 and 12 did not show inhibition of contraction up to 5.000 nM and 10.000 nM, respectively. These findings suggest that there is no agonist effect at m and k opioid receptors. In MVD, the tested compounds showed ⁇ -selective agonism.
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SK1396-96A SK139696A3 (en) | 1994-05-18 | 1995-05-09 | New agonist compounds |
PL95317250A PL317250A1 (en) | 1994-05-18 | 1995-05-09 | Novel agonistic compounds |
AU25818/95A AU690281B2 (en) | 1994-05-18 | 1995-05-09 | New agonist compounds |
US08/507,365 US5886001A (en) | 1994-05-18 | 1995-05-09 | Agonist compounds |
MX9605604A MX9605604A (en) | 1995-05-09 | 1995-05-09 | New agonist compounds. |
BR9507656A BR9507656A (en) | 1994-05-18 | 1995-05-09 | Compound use of a compound Pharmaceutical composition and processes for the treatment of a patient suffering from pain and for the preparation of a compound |
EP95920329A EP0759923A1 (en) | 1994-05-18 | 1995-05-09 | New agonist compounds |
JP7529554A JPH10500132A (en) | 1994-05-18 | 1995-05-09 | New agonist compounds |
NZ287177A NZ287177A (en) | 1994-05-18 | 1995-05-09 | Morphinane derivatives; medicaments |
CA002189139A CA2189139A1 (en) | 1994-05-18 | 1995-05-09 | New agonist compounds |
IS4381A IS4381A (en) | 1994-05-18 | 1996-11-08 | New agitators |
NO964871A NO964871D0 (en) | 1994-05-18 | 1996-11-15 | New agonist compounds |
FI964576A FI964576A0 (en) | 1994-05-18 | 1996-11-15 | New agonist associations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9401727A SE9401727D0 (en) | 1994-05-18 | 1994-05-18 | New compounds I |
SE9401727-4 | 1994-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995031464A1 true WO1995031464A1 (en) | 1995-11-23 |
Family
ID=20394058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1995/000504 WO1995031464A1 (en) | 1994-05-18 | 1995-05-09 | New agonist compounds |
Country Status (18)
Country | Link |
---|---|
US (1) | US5886001A (en) |
EP (1) | EP0759923A1 (en) |
JP (1) | JPH10500132A (en) |
CN (1) | CN1152314A (en) |
AU (1) | AU690281B2 (en) |
BR (1) | BR9507656A (en) |
CA (1) | CA2189139A1 (en) |
FI (1) | FI964576A0 (en) |
HU (1) | HU9603171D0 (en) |
IL (1) | IL113627A0 (en) |
IS (1) | IS4381A (en) |
NO (1) | NO964871D0 (en) |
NZ (1) | NZ287177A (en) |
PL (1) | PL317250A1 (en) |
SE (1) | SE9401727D0 (en) |
SK (1) | SK139696A3 (en) |
WO (1) | WO1995031464A1 (en) |
ZA (1) | ZA953699B (en) |
Cited By (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849731A (en) * | 1995-09-26 | 1998-12-15 | Toray Industries, Inc. | Indole derivatives and medical application thereof |
EP0894799A1 (en) * | 1997-01-16 | 1999-02-03 | Toray Industries, Inc. | Indolomorphinane derivatives and remedies/preventives for cerebral disorders |
WO2000008027A1 (en) * | 1998-08-06 | 2000-02-17 | Regents Of The University Of Minnesota | Kappa (op2) opioid receptor antagonists |
WO2005033073A2 (en) | 2003-10-01 | 2005-04-14 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
US7232829B2 (en) | 2001-04-06 | 2007-06-19 | Regents Of The University Of Minnesota | Therapeutic compounds and methods |
US7576207B2 (en) | 2006-04-06 | 2009-08-18 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
US7598261B2 (en) | 2005-03-31 | 2009-10-06 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
WO2011076363A1 (en) | 2009-12-23 | 2011-06-30 | Universitaet Innsbruck | Morphinan-6-one compounds for the treatment or prevention of neurodegenerative diseases |
EP2399577A1 (en) | 2006-09-12 | 2011-12-28 | Adolor Corporation | Use of N-containing spirocompounds for the enhancement of cognitive function |
WO2012088494A1 (en) * | 2010-12-23 | 2012-06-28 | Pheonix Pharmalabs, Inc. | Novel morphinans useful as analgesics |
WO2013168011A1 (en) * | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
US9102649B1 (en) | 2014-09-29 | 2015-08-11 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9174931B2 (en) | 2013-06-04 | 2015-11-03 | Cellix Bio Private Limited | Compositions for the treatment of diabetes and pre-diabetes |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9580383B2 (en) | 2012-05-23 | 2017-02-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
US9642915B2 (en) | 2012-05-07 | 2017-05-09 | Cellix Bio Private Limited | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
US9725404B2 (en) | 2014-10-27 | 2017-08-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9738631B2 (en) | 2012-05-07 | 2017-08-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9765020B2 (en) | 2012-05-23 | 2017-09-19 | Cellix Bio Private Limited | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis |
US9771355B2 (en) | 2014-09-26 | 2017-09-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US10227301B2 (en) | 2015-01-06 | 2019-03-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9717629D0 (en) * | 1997-08-21 | 1997-10-22 | Johnson Matthey Plc | Removal of residual organic solvents |
WO2002080919A1 (en) * | 2001-04-06 | 2002-10-17 | Regents Of The University Of Minnesota | Therapeutic compounds and methods |
DE10229842A1 (en) * | 2002-07-03 | 2004-02-05 | Helmut Prof. Dr. Schmidhammer | Morphinane derivatives and their quaternary ammonium salts substituted in position 14, production process and use |
US9321116B2 (en) * | 2009-03-05 | 2016-04-26 | United Technologies Corporation | Cold metal transfer gas metal arc welding apparatus and method of operation |
HU231191B1 (en) | 2013-04-15 | 2021-08-30 | Szegedi Tudományegyetem | Isotope containing morphine molecules |
ES2784690T3 (en) | 2013-12-05 | 2020-09-29 | Univ Bath | New opioid compounds and their uses |
WO2016073615A1 (en) | 2014-11-07 | 2016-05-12 | Regents Of The University Of Minnesota | Salts and compositions useful for treating disease |
WO2017165558A1 (en) | 2016-03-22 | 2017-09-28 | Regents Of The University Of Minnesota | Combination for treating pain |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816586A (en) * | 1987-07-29 | 1989-03-28 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
US5223507A (en) * | 1992-01-21 | 1993-06-29 | G. D. Searle & Co. | Method of using opioid compounds as delta opioid selective agonist analgesics |
US5225417A (en) * | 1992-01-21 | 1993-07-06 | G. D. Searle & Co. | Opioid agonist compounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2906654B2 (en) * | 1989-11-28 | 1999-06-21 | 東レ株式会社 | Immunosuppressant and method for producing the same |
ES2121988T3 (en) * | 1992-01-23 | 1998-12-16 | Toray Industries | DERIVATIVE OF MORFINANO AND MEDICINAL USE. |
CN1043766C (en) * | 1992-09-29 | 1999-06-23 | 东丽株式会社 | Indole derivative and preparation and pharmaceutical using of same |
US5464841A (en) * | 1993-11-08 | 1995-11-07 | Univ Minnesota | Use of delta opioid receptor antagonists to treat immunoregulatory disorders |
US5780479A (en) * | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
-
1994
- 1994-05-18 SE SE9401727A patent/SE9401727D0/en unknown
-
1995
- 1995-05-07 IL IL11362795A patent/IL113627A0/en unknown
- 1995-05-08 ZA ZA953699A patent/ZA953699B/en unknown
- 1995-05-09 WO PCT/SE1995/000504 patent/WO1995031464A1/en not_active Application Discontinuation
- 1995-05-09 CA CA002189139A patent/CA2189139A1/en not_active Abandoned
- 1995-05-09 HU HU9603171A patent/HU9603171D0/en unknown
- 1995-05-09 BR BR9507656A patent/BR9507656A/en not_active Application Discontinuation
- 1995-05-09 CN CN95194032A patent/CN1152314A/en active Pending
- 1995-05-09 JP JP7529554A patent/JPH10500132A/en not_active Abandoned
- 1995-05-09 US US08/507,365 patent/US5886001A/en not_active Expired - Fee Related
- 1995-05-09 PL PL95317250A patent/PL317250A1/en unknown
- 1995-05-09 SK SK1396-96A patent/SK139696A3/en unknown
- 1995-05-09 EP EP95920329A patent/EP0759923A1/en not_active Withdrawn
- 1995-05-09 AU AU25818/95A patent/AU690281B2/en not_active Ceased
- 1995-05-09 NZ NZ287177A patent/NZ287177A/en unknown
-
1996
- 1996-11-08 IS IS4381A patent/IS4381A/en unknown
- 1996-11-15 FI FI964576A patent/FI964576A0/en unknown
- 1996-11-15 NO NO964871A patent/NO964871D0/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816586A (en) * | 1987-07-29 | 1989-03-28 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists |
US5223507A (en) * | 1992-01-21 | 1993-06-29 | G. D. Searle & Co. | Method of using opioid compounds as delta opioid selective agonist analgesics |
US5225417A (en) * | 1992-01-21 | 1993-07-06 | G. D. Searle & Co. | Opioid agonist compounds |
Non-Patent Citations (1)
Title |
---|
J. MED. CHEM., Volume 35, 1992, P.S. PORTOGHESE et al., "Opioid Agonist and Antagonist Activities of Morphindoles Related to Naltrindole", pages 4325-4329. * |
Cited By (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849731A (en) * | 1995-09-26 | 1998-12-15 | Toray Industries, Inc. | Indole derivatives and medical application thereof |
EP0894799A1 (en) * | 1997-01-16 | 1999-02-03 | Toray Industries, Inc. | Indolomorphinane derivatives and remedies/preventives for cerebral disorders |
US6156762A (en) * | 1997-01-16 | 2000-12-05 | Toray Industries, Inc. | Indolomorphinan derivative and agent for curing and preventing cerebral disorder |
EP0894799A4 (en) * | 1997-01-16 | 2001-08-16 | Toray Industries | Indolomorphinane derivatives and remedies/preventives for cerebral disorders |
WO2000008027A1 (en) * | 1998-08-06 | 2000-02-17 | Regents Of The University Of Minnesota | Kappa (op2) opioid receptor antagonists |
US7232829B2 (en) | 2001-04-06 | 2007-06-19 | Regents Of The University Of Minnesota | Therapeutic compounds and methods |
US7638527B2 (en) | 2003-10-01 | 2009-12-29 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
US8071611B2 (en) | 2003-10-01 | 2011-12-06 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
WO2005033073A2 (en) | 2003-10-01 | 2005-04-14 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
US7338962B2 (en) | 2003-10-01 | 2008-03-04 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
US7906646B2 (en) | 2003-10-01 | 2011-03-15 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
US8022060B2 (en) | 2005-03-31 | 2011-09-20 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
US7598261B2 (en) | 2005-03-31 | 2009-10-06 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
US7576207B2 (en) | 2006-04-06 | 2009-08-18 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
EP2399577A1 (en) | 2006-09-12 | 2011-12-28 | Adolor Corporation | Use of N-containing spirocompounds for the enhancement of cognitive function |
WO2011076363A1 (en) | 2009-12-23 | 2011-06-30 | Universitaet Innsbruck | Morphinan-6-one compounds for the treatment or prevention of neurodegenerative diseases |
EP2340832A1 (en) | 2009-12-23 | 2011-07-06 | Universität Innsbruck | Morphinan-6-one compounds for the treatment or prevention of neurodegenerative diseases |
WO2012088494A1 (en) * | 2010-12-23 | 2012-06-28 | Pheonix Pharmalabs, Inc. | Novel morphinans useful as analgesics |
US8987293B2 (en) | 2010-12-23 | 2015-03-24 | Phoenix Pharmalabs, Inc. | Morphinans useful as analgesics |
US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
US9738631B2 (en) | 2012-05-07 | 2017-08-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9642915B2 (en) | 2012-05-07 | 2017-05-09 | Cellix Bio Private Limited | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
WO2013168011A1 (en) * | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
US9765020B2 (en) | 2012-05-23 | 2017-09-19 | Cellix Bio Private Limited | Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis |
US9580383B2 (en) | 2012-05-23 | 2017-02-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9403793B2 (en) | 2012-07-03 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
US9670153B2 (en) | 2012-09-08 | 2017-06-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9174931B2 (en) | 2013-06-04 | 2015-11-03 | Cellix Bio Private Limited | Compositions for the treatment of diabetes and pre-diabetes |
US9840472B2 (en) | 2013-12-07 | 2017-12-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of mucositis |
US9771355B2 (en) | 2014-09-26 | 2017-09-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
US9102649B1 (en) | 2014-09-29 | 2015-08-11 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
US9988340B2 (en) | 2014-09-29 | 2018-06-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9725404B2 (en) | 2014-10-27 | 2017-08-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
US10227301B2 (en) | 2015-01-06 | 2019-03-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
US10343994B2 (en) | 2015-01-06 | 2019-07-09 | Mahesh Kandula | Compositions and methods for the treatment of inflammation and pain |
Also Published As
Publication number | Publication date |
---|---|
CA2189139A1 (en) | 1995-11-23 |
FI964576A (en) | 1996-11-15 |
NO964871L (en) | 1996-11-15 |
US5886001A (en) | 1999-03-23 |
BR9507656A (en) | 1997-09-23 |
SK139696A3 (en) | 1997-05-07 |
JPH10500132A (en) | 1998-01-06 |
HU9603171D0 (en) | 1997-01-28 |
AU2581895A (en) | 1995-12-05 |
EP0759923A1 (en) | 1997-03-05 |
PL317250A1 (en) | 1997-04-01 |
AU690281B2 (en) | 1998-04-23 |
IL113627A0 (en) | 1995-08-31 |
SE9401727D0 (en) | 1994-05-18 |
NZ287177A (en) | 1997-11-24 |
ZA953699B (en) | 1995-11-20 |
FI964576A0 (en) | 1996-11-15 |
IS4381A (en) | 1996-11-08 |
CN1152314A (en) | 1997-06-18 |
NO964871D0 (en) | 1996-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5886001A (en) | Agonist compounds | |
EP0759922B1 (en) | New antagonist compounds | |
US4816586A (en) | Delta opioid receptor antagonists | |
US20070167474A1 (en) | Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin | |
US20160257677A1 (en) | Large substitutent, non-phenolic opioids and methods of use thereof | |
EP0614898B1 (en) | Indole derivative, process for producing the same, and medicinal use thereof | |
RU2306314C2 (en) | 6-amino-morphinane derivatives and uses thereof | |
WO1998043978A1 (en) | Morphinane derivatives and medicinal use thereof | |
ITMI951900A1 (en) | REPLACED HYDROISOKINOLINIC DERIVATIVES | |
JP4292738B2 (en) | Indole derivatives and their pharmaceutical use | |
MXPA96005604A (en) | New agonis compounds | |
CA2189140C (en) | New antagonist compounds | |
DK161149B (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF N-SUBSTITUTED 6-OXAMORPHINANES AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF | |
AU2011221389A1 (en) | Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin | |
AU1402497A (en) | New process for the preparation of morphinans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95194032.5 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08507365 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 287177 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2189139 Country of ref document: CA Ref document number: 139696 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995920329 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 964576 Country of ref document: FI Ref document number: PA/a/1996/005604 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1996-3379 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1995920329 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: PV1996-3379 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995920329 Country of ref document: EP |